Hemispherx Biopharma nets $14.2mm with private sale of shares

Hemispherx Biopharma (developing infectious disease, cancer, and immunology drug candidates) has netted $14.2mm through the sale of 13.6mm shares at $1.10 each (a 53% premium) to two institutional investors. The backers also received Series A warrants to buy another 6.1mm common shares; the Series I five-year warrants enable the holder to purchase shares for $1.65 each and the Series II warrants are exercisable for 3mm shares within 45 days at $1.10. Rodman & Renshaw was the placement agent.